Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

AMG 334 is being co-developed by Amgen and Novartis. Amgen has marketing rights in the US, Canada and Japan, while Novartis will sell the drug in Europe and the rest of the world if approved.

Amgen has initiated a new Phase I trial for AMG-513, an innovative drug candidate with potential indications for obesity, which is a significant move consistent with the company’s broader ...

There are 4,096 funds or institutions reporting positions in Amgen. This is an increase of 50 owner(s) or 1.24% in the last quarter. Average portfolio weight of all funds dedicated to AMG is 0.55% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Join Brian Lanman of Amgen as he outlines the strategies used to overcome these challenges, the screening approaches employed to identify starting points for these efforts, and the optimization ...

Amgen's CEO, Chairman and President Bob Bradway urged analysts to “stay tuned” for data on the last earnings call, so “stay tuned” for an update next week. AMG 193 is also early stage ...

THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects ...